Because of its excellent safety profile and broad spectrum of activity, ivermectin is catalogued by the World Health Organisation as an essential medicine and is regarded by many as a "magic bullet" for global health.
The Japanese Journal of Antibiotics: Global trends in clinical studies of ivermectin (authored by 4 doctors, including Satoshi Ōmura, winner of the Nobel Prize in 2015 for his work on ivermectin)
As of the 27th of February 2021, the results of 42 clinical studies worldwide have undergone meta-analysis and concluded that ivermectin is effective in the treatment and prevention of COVID-19. In the UK, a consensus-based recommendation by 75 healthcare professionals from 17 countries around the world has been carried out and submitted to the WHO to further encourage the issuance of guidelines for the use of ivermectin in the treatment and prevention of COVID-19.
The Journal of Antibiotics: Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations
Antiviral (e.g. HIV, dengue, encephalitis)
Recent research has confounded the belief, held for most of the past 40 years, that ivermectin was devoid of any antiviral characteristics. Ivermectin has been found to potently inhibit replication of the yellow fever virus, with EC50 values in the sub-nanomolar range. It also inhibits replication in several other flaviviruses, including dengue, Japanese encephalitis and tick-borne encephalitis, probably by targeting non-structural 3 helicase activity. Ivermectin inhibits dengue viruses and interrupts virus replication, bestowing protection against infection with all distinct virus serotypes, and has unexplored potential as a dengue antiviral.
Ivermectin has also been demonstrated to be a potent broad-spectrum specific inhibitor of importin α/β-mediated nuclear transport and demonstrates antiviral activity against several RNA viruses by blocking the nuclear trafficking of viral proteins. It has been shown to have potent antiviral action against HIV-1 and dengue viruses, both of which are dependent on the importin protein superfamily for several key cellular processes. Ivermectin may be of import in disrupting HIV-1 integrase in HIV-1 as well as NS-5 (non-structural protein 5) polymerase in dengue viruses.
Monash Biomedicine Discovery Institute: Lab experiments show anti-parasitic drug, Ivermectin, eliminates SARS-CoV-2 in cells in 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint venture of the University of Melbourne and Royal Melbourne Hospital, has shown that an anti-parasitic drug already available around the world kills the virus within 48 hours.
The Monash Biomedicine Discovery Institute’s Dr Kylie Wagstaff, who led the study, said the scientists showed that the drug, Ivermectin, stopped the SARS-CoV-2 virus growing in cell culture within 48 hours.
“We found that even a single dose could essentially remove all viral RNA by 48 hours and that even at 24 hours there was a really significant reduction in it,” Dr Wagstaff said.
Ivermectin is an FDA-approved anti-parasitic drug that has also been shown to be effective in vitro against a broad range of viruses including HIV, Dengue, Influenza and Zika virus.
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
[A] significant difference was found in patients with higher median plasma IVM levels (72% IQR 59–77) versus untreated controls (42% IQR 31–73) (p = 0·004).
U.S. Pharmacist: Common Supplements Might Reduce COVID Severity
For prophylaxis, the medical school recommends vitamin C (500 mg) and quercetin (250 mg-500 mg twice a day) with zinc (75 mg-100 mg per day), melatonin (0.3 mg-2 mg) each night, and vitamin D3 (1,000-4,000 IU per day). Famotidine (20 mg-40 mg per day) may be added to the mix. For patients with mild symptoms, EVMS recommends the same combination, with optional additions of ivermectin (150 ug-200 ug per kg as a single dose), and one low-dose or regular aspirin per day.
The Journal of Antibiotics: The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article
Although several drugs received Emergency Use Authorization for COVID-19 treatment with unsatisfactory supportive data, Ivermectin, on the other hand, has been sidelined irrespective of sufficient convincing data supporting its use.
Colombia Médica: COVID-19: The Ivermectin African Enigma
[A] mass public health preventive campaign against COVID-19 may have taken place, inadvertently, in some African countries with massive community ivermectin use...
Los Angeles Times: The FDA didn’t ‘approve’ Pfizer’s COVID-19 vaccine. Here’s why (Dec 2020)
Another important condition for issuing an EUA is that “there are no adequate, approved, and available alternatives” to the product being authorized.
Matt Taibbi: Why Has "Ivermectin" Become a Dirty Word?
At the worst moment, Internet censorship has driven scientific debate itself underground.
If the FDA were driven by science and evidence, it would give an emergency-use authorization for ivermectin for Covid-19. Instead, the FDA asserts without evidence that ivermectin is dangerous.
"Uttar Pradesh was the first state in the country to introduce large-scale prophylactic and therapeutic use of Ivermectin. In May-June 2020, a team at Agra, led by Dr Anshul Pareek, administered Ivermectin to all RRT team members in the district on an experimental basis. It was observed that none of them developed Covid-19 despite being in daily contact with patients who had tested positive for the virus," Uttar Pradesh State Surveillance Officer Vikssendu Agrawal said.
International Journal of Infectious Diseases: Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico
"TNR4 is a multidrug therapy (Ivermectin, Azithromycin, Montelukast, and ASA) for COVID-19 cases. TNR4 increased the likelihood of recovery 3.4 times in ambulatory COVID-19 cases. The multidrug therapy TNR4 reduced the risk of hospitalization by 75%. The multidrug therapy TNR4 reduced the risk of death by 81%.
Mainichi: ノーベル賞学者・大村智博士が「予防はワクチン 治療はイベルメクチン」
Dr. Satoshi Omura, Nobel Prize scholar: "Vaccines for prevention, ivermectin for treatment"
Nikkei: 東京都医師会、イベルメクチン投与を提言 重症化予防で
Tokyo Metropolitan Medical Association recommends ivermectin administration to prevent serious illness 📺
Yomiuri Shimbun: 「今こそイベルメクチンを使え」東京都医師会の尾崎治夫会長が語ったその効能
"Now is the time to use ivermectin," said Haruo Ozaki, chairman of the Tokyo Metropolitan Medical Association
New Microbes and New Infections: Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19
During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments.
[T]he drug is considered safe enough to give to almost everyone except the youngest infants and pregnant women.
C-SPAN: Medical Response to COVID-19 (Pierre Kory, M.D., pulmonologist at St. Luke's Aurora Medical Center, discusses the efficacy of ivermectin from the 29m26s mark)
The Senate Homeland Security and Governmental Affairs Committee heard from medical professionals who advocate for alternative COVID-19 treatments and mitigation measures to those of the National Institutes of Health, Centers for Disease Control and Prevention, and World Health Organization.
Philippine Daily Inquirer: Uttar Pradesh is ivermectin’s best practice success story
In last week's column, we wrote about the amazing outcome many states in India like Uttar Pradesh and Delhi have attained with an ivermectin-based multidrug prevention and early treatment kits. With a population of 241 million, more than twice that of the Philippines, Uttar Pradesh has been averaging less than 100 new COVID cases daily in the last three months, and less than 20 a day in the last three weeks. The deaths average one a day in the last six weeks. More than half of its districts or provinces have been declared COVID-free with zero active cases. One can't possibly attribute it to its anti-COVID vaccination, because it's one of the slowest among the Indian states in its vaccination rollout, with less than 5 percent of its population fully vaccinated.
Honolulu Star-Advertiser: Doctors grow frustrated over COVID-19 denial, misinformation
The Associated Press asked six doctors from across the country to describe the types of misinformation and denial they see on a daily basis and how they respond to it. They describe being aggravated at the constant requests to be prescribed the veterinary parasite drug Ivermectin, with patients lashing out at doctors when they are told that it’s not a safe coronavirus treatment.
Nebraska Attorney General Doug Peterson issued his opinion Friday that health care providers can legally prescribe off-label medications like Ivermectin... "[W]e address only the off-label early treatment options discussed in this opinion and conclude that the available evidence suggests they might work for some people. Allowing physicians to consider these early treatments will free them to evaluate additional tools that could save lives, keep patients out of the hospital, and provide relief for our already strained health care system."
5 hospitalized. 0 dead. 4000 recovered. 5 pharmacist threats. 1 medical board complaint. 1 lawyer retained. Hundreds of medication transfers for pharmacist refusals.
The Jerusalem Post: Israeli scientist says COVID-19 could be treated for under $1/day
Nearly 72% of volunteers treated with ivermectin tested negative for the virus by day six. In contrast, only 50% of those who received the placebo tested negative. In addition, the study looked at culture viability, meaning how infectious the patients were, and found that only 13% of ivermectin patients were infectious after six days, compared with 50% of the placebo group – almost four times as many.
Dr. John Campbell: New Pfizer drug and ivermectin
A brief message to world leaders: Come on ya all
An Illinois family whose loved one was "desperately ill" and hospitalized earlier this month with COVID-19 says he's now home and doing well after a judge had to order a Naperville hospital to treat him with Ivermectin. On Nov. 8, the family won a legal battle to gain approval to administer the controversial drug to 71-year-old Sun Ng, who had been on a ventilator since October 19.
The Journal of Antibiotics: The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review
Although several drugs received emergency use authorization for COVID-19 treatment with unsatisfactory supportive data, ivermectin, on the other hand, has been sidelined. Nevertheless, many countries adopted ivermectin as one of the first-line treatment options for COVID-19.
Hindustan Times: Covid-19 medicine kits’ distribution begins in Varanasi
Azithromycin 500, Ivermectin 12 mg, Vitamin D3, Vitamin C, Zinc, Vitamin B complex and paracetamol tablets are available for those above 12 years.
Journal of Infection and Chemotherapy: Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis
The administration of ivermectin improved GI complications and VFD in ventilated patients with COVID-19. The beneficial influence of ivermectin on the intestines may improve outcome in these patients.
Cureus Journal of Medical Science: Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching
The regular use of ivermectin led to a 68% reduction in COVID-19 mortality (25 [0.8%] versus 79 [2.6%] among ivermectin non-users; RR, 0.32; 95% CI, 0.20-0.49; p < 0.0001). When adjusted for residual variables, reduction in mortality rate was 70% (RR, 0.30; 95% CI, 0.19-0.46; p < 0.0001). There was a 56% reduction in hospitalization rate (44 versus 99 hospitalizations among ivermectin users and non-users, respectively; RR, 0.44; 95% CI, 0.31-0.63; p < 0.0001). After adjustment for residual variables, reduction in hospitalization rate was 67% (RR, 0.33; 95% CI, 023-0.66; p < 0.0001).
Asahi Shimbun: 興和、「イベルメクチン」のオミクロン株への抗ウイルス効果を確認
Kowa confirms antiviral effect of "ivermectin" on Omicron strain
American Thinker: Why Ivermectin was Disappeared
Given all this, I think it's easy to suspect that the FDA, the NIH, and the CDC actually understand the potential benefits of Ivermectin and other repurposed drugs. But they also realize that these medications threaten the profits of the pharmaceutical industry with which they are financially entwined.
International Journal of Infectious Diseases: Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database
Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir. To our knowledge, this is the largest association study of patients with COVID-19, mortality and ivermectin.
Interviews with doctors, nurses, and others whose lives were saved by ivermectin:
Many more interviews here
/misc | Aug 28, 2021
Subscribe or visit the archives.